secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001193125-24-072048
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio receives FDA Orphan Drug Designation for CABA-201 in systemic sclerosis
--------------------------------------------------------------------------------

- FDA grants Orphan Drug Designation to CABA-201 for systemic sclerosis, a rare autoimmune disease.
- CABA-201 is a fully human CD19-CAR T cell therapy being studied in Phase 1/2 RESET-SSc trial.
- ODD provides tax credits, waived user fees, and potential 7-year marketing exclusivity upon approval.
- Systemic sclerosis affects <200,000 US patients; average survival ~12 years after diagnosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524072048/0001193125-24-072048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524072048/d812029d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-072048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer